New hope for nail psoriasis: tildrakizumab shows promise in trial
NCT ID NCT03897075
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 study tested the drug tildrakizumab in 99 adults with moderate to severe nail psoriasis. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and reduced pain. The trial is complete, and results may help determine if tildrakizumab is a safe and effective treatment for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tildrakizumab
What this could lead to
If successful, this could provide a new treatment option for people with stubborn nail psoriasis, improving nail appearance and reducing pain.
What could go wrong
This is a completed Phase 3 trial with 99 participants, so results are specific to this group. Tildrakizumab may not work for everyone and can have side effects like any medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Dermatology & CRI (Site 18)
Encinitas, California, 92007, United States
-
Center for Clinical Studies (Site 11)
Houston, Texas, 77004, United States
-
Center for Clinical Studies Cypress (Site 17)
Cypress, Texas, 77433, United States
-
Clinical Partners, LLC (Site 08)
Johnston, Rhode Island, 02919, United States
-
Clinical Science Institute (Site 14)
Santa Monica, California, 90404, United States
-
Dermatology Research Associates (Site 09)
Los Angeles, California, 90045, United States
-
First OC Dermatology (Site 07)
Fountain Valley, California, 92708, United States
-
Florida Academic Centers Research and Education, LLC (Site 21)
Coral Gables, Florida, 33134, United States
-
Forest Hills Dermatology Group (Site 04)
Forest Hills, New York, 11375, United States
-
Fremantle Dermatology (Site 40)
Fremantle, WAUS, 6160, Australia
-
North Eastern Health Specialists (Site 46)
Campbelltown, South Australia, 5073, Australia
-
Premier Dermatology (Site 47)
Kogarah, New South Wales, 2217, Australia
-
Progressive Clinical Research (Site 27)
San Antonio, Texas, 78213, United States
-
Renstar Medical Research (Site 23)
Ocala, Florida, 34470, United States
-
Skin Health Institute Inc. (Site 43)
Carlton, Victoria, 3053, Australia
-
St George Dermatology & Skin Cancer Centre (Site 45)
Kogarah, New South Wales, 2217, Australia
-
Veracity Clinical Research/ Specialist Connect(Site 44)
Woolloongabba, QSLD, 4102, Australia